Skip to main content
. 2021 May 4;26(7):e1161–e1170. doi: 10.1002/onco.13786

Figure 4.

Figure 4

Progression‐free survival (PFS) using first‐line therapy in patients with MSS and MSI‐H (A), PFS using anti‐EGFR therapy between HER2 mutated and amplification cases (B), and PFS using PD‐1 antibody between MSI‐H with and without HER2 mutation (C). Abbreviations: EGFR, epidermal growth factor receptor; HER2, human epidermal growth receptor 2; MSI‐H, microsatellite instability‐high; MSS, microsatellite stability; PD‐1, programmed death‐1.